Studies of a vascular-acting photosensitizer, Pd-bacteriopheophorbide (Tookad), in normal canine prostate and spontaneous canine prostate cancer

✍ Scribed by Zheng Huang; Qun Chen; David Luck; Jill Beckers; Brian C. Wilson; Nadira Trncic; Susan M. LaRue; Dominique Blanc; Fred W. Hetzel

• Publisher: John Wiley and Sons
• Year: 2005
• Tongue: English
• Weight: 232 KB
• Volume: 36
• Category: Article
• ISSN: 0196-8092
• DOI: 10.1002/lsm.20177

✦ Synopsis

Abstract

Background and Objectives

Photodynamic therapy (PDT) mediated with Tookad (Pd‐bacteriopheophorbide, WST09) was investigated pre‐clinically as part of a program to develop an alternative modality for treating prostate cancer.

Study Design/Materials and Methods

Spontaneous canine prostate cancer and normal canine prostate were used as the animal models. Interstitial PDT was performed by IV infusion of the photosensitizer and irradiating the prostates with a diode laser (763 nm). The prostates were harvested 1‐week post‐PDT and subjected to histopathologic examinations. The effects of the drug doses and light doses were studied for one‐ and two‐session PDT. Pharmacokinetics were studied using HPLC assay. The feasibility of using perfusing CT scans for assessing PDT lesions was also evaluated.

Results

Tookad is a vascular‐acting drug and clears rapidly from the circulation. Tookad‐PDT‐induced lesions, in both normal and cancerous prostates, were characterized by marked hemorrhagic necrosis.

Conclusions

Tookad‐PDT is very effective in ablating prostatic tissue through its vascular effects. Lasers Surg. Med. © 2005 Wiley‐Liss, Inc.